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 Abstract 
  Background:   NADPH oxidase is an important enzyme involved in the generation of reactive 
oxygen species in acute kidney injury (AKI). Its key subunit, p22  phox  , is encoded by the highly 
polymorphic  CYBA  gene.  Methods:  We examined the associations of  CYBA  gene polymorphisms 
across the   CYBA   locus (rs8854, rs3794624, rs4673, rs4782390, and rs1049255) with dialysis re-
quirement or in-hospital death in 256 hospitalized adults with AKI. Dominant and haplotype 
multivariable logistic regression analyses were performed, adjusted for sex, race, age, and se-
verity of illness.   Results:   The baseline characteristics of the patients were not different among 
genotype groups with the exception of a lower prevalence of sepsis and shock in the   CYBA  
rs8854 A-allele group; a higher prevalence of shock in the  CYBA  rs4782390 T-allele group, and a 
higher APACHE II score in the   CYBA   rs1049255 G-allele group. The   CYBA   rs8854 A-allele had an 
adjusted odds ratio (OR) of 0.41 (95% confidence interval, CI, 0.18–0.96) for the outcome of di-
alysis requirement or in-hospital death. The   CYBA   rs4673 T-allele and rs1049255 G-allele had 
unadjusted ORs of 1.69 (95% CI 1.03–2.79) and 1.66 (95% CI 1.01–2.73) for the composite out-
come, respectively, which became non-significant after multivariable adjustment. The remain-
  Published online: October 21, 2011 
EXTRA
  Bertrand L. Jaber, MD, MS 
This is an Open Access article licensed under the terms of the Creative Commons Attribution- 
NonCommercial-NoDerivs 3.0 License (www.karger.com/OA-license), applicable to the online 
version of the article only. Distribution for non-commercial purposes only.
  Department of Medicine, St. Elizabeth’s Medical Center 
  736 Cambridge Street 
  Boston, MA 02135 (USA) 
  Tel. +1 617 562 7830, E-Mail bertrand.jaber    @   steward.org 
www.karger.com/nne
 DOI:  10.1159/000333017 113
Nephron Extra 2011;1:112–123
 DOI:  10.1159/000333017 
EXTRA
  Perianayagam et al.:   CYBA   Gene Polymorphisms in Acute Kidney Injury 
www.karger.com/nne
  © 2011 S. Karger AG, Basel 
  Published online: October 21, 2011 
ing 2 polymorphisms were not associated with the outcomes of interest. Finally, the presence 
of the   CYBA   A-A-G-G haplotype (generated from rs4782390, rs4673, rs3794624, and rs8854, all 
in Hardy-Weinberg equilibrium) was associated with an elevated OR of 1.81 (95% CI 1.07–3.08) 
for dialysis requirement or in-hospital death, which was attenuated after multivariable adjust-
ment (OR 1.80; 95% CI 0.99–3.29).   Conclusion:   This study identifies several polymorphisms 
spanning the entire   CYBA   gene locus and a common haplotype as risk markers for dialysis re-
quirement or in-hospital death in patients with AKI. Additional studies are needed to validate 
these findings.    Copyright © 2011 S. Karger AG, Basel 
 Introduction   
  Acute kidney injury (AKI) is a common condition and is associated with an increased 
risk of in-hospital mortality and heightened resource consumption, including prolonged 
hospitalization and greater healthcare expenditures   [1, 2]  . Although reactive oxygen spe-
cies (ROS) have been incriminated in the pathogenesis and evolution of AKI   [3–9]  , there is 
significant unexplained variability in the prediction of adverse kidney-related outcomes 
 [10,  11] .
  In recent years, several genetic polymorphisms have been explored as potential determi-
nants of disease severity and adverse outcomes in patients with AKI   [12–18]  . An important 
source of ROS in AKI is NADPH oxidase (NOX), an enzyme complex that primarily pro-
duces superoxide   [19]  . This enzyme has multiple components, including 2 transmembrane 
subunits (gp91  phox   and p22  phox  ), 3 cytosolic subunits (p40  phox ,  p47 phox  , and p67  phox  ), and a 
GTP-binding protein (p21). 
  T h e   p2 2  phox   subunit is the final transporter in the chain transferring electrons from 
NADPH to molecular oxygen, and is encoded by the    subunit of the cytochrome b  245   (CYBA)  
gene, which is located on chromosome 16q24. Several polymorphisms in the  CYBA  gene have 
been described, some of which have been associated with increased   [20]   or decreased NOX 
activity   [21]  , as well as reduced ROS generation   [22, 23]  . Genetic variation in the expression 
of this key enzyme might account for the interindividual variability observed in the mani-
festation of AKI. The aim of the present study was to examine whether 5 key polymorphisms 
in the   CYBA   gene locus and corresponding haplotypes are associated with disease severity 
and adverse outcome in hospitalized AKI patients. 
  Patients  and  Methods   
  Study Design and Participants 
  This was a prospective cohort study of hospitalized AKI patients, which was conducted 
at two tertiary care hospitals (Boston, Mass., USA). All consecutive hospitalized adults with 
AKI, in whom nephrology consultation was requested, were eligible for enrollment. AKI was 
defined according to the criteria by Hou et al.   [24]  , i.e. a rise in serum creatinine by 0.5, 1.0, 
or 1.5 mg/dl from a baseline level   ^  1.9, 2.0–4.9, or   6  5.0 mg/dl, respectively. This definition 
was adopted prior to the development of the more recent AKI network consensus definition 
  [25]  . However, we used this classification to categorize AKI stages.
    Exclusion criteria were age   !  18 years, pregnancy, long-term dialysis, organ transplanta-
tion within the prior year, and presence of acute obstructive uropathy. Institutional review 
board approval was granted, and written informed consent was obtained from all partici-
pants or next of kin.114
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  D a t a   C o l l e c t i o n  
 Hospital records were reviewed prospectively to retrieve information on baseline demo-
graphic characteristics, coexisting conditions, and kidney-related variables, including serial 
serum creatinine values and 24-hour urine output at enrollment. Sepsis was ascertained us-
ing the systemic inflammatory response syndrome criteria   [26]  , and two severity-of-illness 
scores were calculated, the APACHE II (Acute Physiology and Chronic Health Evaluation) 
score   [27]   and the MOF (Multiple Organ Failure) score   [28]  . Preexisting chronic kidney dis-
ease was defined on the basis of a baseline estimated glomerular filtration rate   ! 60  ml/
min/1.73 m  2 , which was calculated using the MDRD (Modification of Diet in Renal Disease) 
equation   [29] . 
    Blood and Urine Sampling 
 At enrollment, EDTA-anticoagulated whole blood and urine were collected. Plasma was 
separated, and the remaining blood was aliquoted for subsequent DNA extraction. Either 
freshly voided urine or urine from the access port of a Foley catheter was obtained, kept on 
ice and processed within 30 min after collection. Samples were centrifuged for 10 min at 
3,000 rpm, treated with a protease inhibitor cocktail (Complete Mini; Roche Diagnostics, 
Mannheim, Germany) and then aliquoted. All samples were stored at –80    °   C.
    Selection Criteria and TaqMan Genotyping Analyses 
  To obtain a comprehensive representation of the genetic variability in the   CYBA   gene 
locus (reference sequence GeneBank accession No. NM 000101.2), we selected the genetic 
variants according to several criteria, including published reports on investigated clinical 
and functional associations; variants with at least 10% minor allele frequency, and variants 
preferentially located in the promoter, coding, non-coding, and untranslated regions (UTR). 
Through this careful selection process, we identified the following 5 polymorphisms of in-
terest in the C  YBA   gene locus: promoter –1442 (G  ]  A, reference single nucleotide polymor-
phism, refSNP, rs8854), intron 1 +383 (G ] A, refSNP rs3794624), exon 4 +242 (C ] T, refSNP 
rs4673), and 3    -UTR +8897 (A  ]  T, refSNP rs4782390), and +640 (A  ]  G, refSNP rs1049255).
  Genomic DNA was prepared from whole blood leukocytes using the QiAmp DNA blood 
kit (Qiagen, Valencia, Calif., USA). DNA samples were then genotyped by combining the 
TaqMan universal PCR master mix with the TaqMan SNP genotyping assay into a 384-well 
plate using the Applied Biosystems 7900HT fast real-time PCR system (Applied Biosystems, 
Foster City, Calif., USA) according to a standardized protocol. Resulting sequences were 
analyzed by the SNP software (SDS version 2.2), which uses an advanced multi-component 
algorithm to calculate distinct allele/marker signal contributions from fluorescence mea-
surements for each sample well during the assay plate read with the SNP auto-caller. The SNP 
auto-caller automatically determines sample genotypes and generates a cluster plot to better 
visualize data across samples. Pairwise patterns of linkage disequilibrium (LD) across the 
  CYBA  gene locus were visualized by Haploview (www.broadinstitute.org), plotting LD as the 
D     parameter (scaled from 0 to 100), and excluding the polymorphism(s) that did not meet 
the Hardy-Weinberg equilibrium. Haplotypes were imputed from the   CYBA   polymorphism 
diploid genotypes using PLINK (http://pngu.mgh.harvard.edu/    purcell/plink/). The most 
frequent haplotype across the 4 polymorphisms in Hardy-Weinberg equilibrium (rs4782390, 
rs4673, rs3794624, and rs8854) was A-A-G-G, and was expressed as the number of chromo-
somal copies of the haplotype (0, 1, and 2) for each patient.
    Measurement of Markers of Oxidative Stress  
  To evaluate whether the   CYBA   gene polymorphisms were associated with markers of 
oxidative stress, we measured plasma nitrotyrosine (a byproduct of superoxide and nitric 115
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oxide generation) and urinary 15-F  2t  -isoprostane (a marker of lipid peroxidation). All mea-
surements were performed in duplicate. In brief, plasma nitrotyrosine was measured by 
sandwich ELISA (OxisResearch, Foster City, Calif., USA; results are reported in n  M ). Urinary 
15-F  2t  -isoprostane was measured by competitive ELISA (Northwest Life Science Specialties, 
LLC, Vancouver, Wash., USA). The results were normalized to urinary creatinine (expressed 
as ng/mg of creatinine). 
  Outcome  Measures 
  Our primary outcome of interest was the composite of dialysis requirement or in-hospi-
tal death. Our secondary outcome was the composite of dialysis requirement, assisted me-
chanical ventilation, or in-hospital death.
  Statistical  Analyses 
 The genotype frequencies were tested for Hardy-Weinberg equilibrium using a standard 
    2  test for any deviation in the observed frequencies. Comparisons between genotype groups 
were made by the Kruskal-Wallis test and the two-tailed Mann-Whitney test for continuous 
variables, and the     2   or Fisher exact test for categorical variables. Results are expressed as 
means (SD), medians, or percentages.
  Using dominant genetic models (i.e., one or two copies of the minor allele), multivariable 
logistic regression analyses were performed to examine the association of each   CYBA   gene 
polymorphism with the aforementioned primary and secondary endpoints. All models were 
adjusted for sex, race, and age (model 1), or sex, race, and the APACHE II score (model 2). 
Sepsis was added as a covariate in sensitivity analyses. The results of the logistic regression 
analyses are displayed as odds ratio (OR) with 95% confidence interval (CI). Using a stepwise 
forward and backward selection process, logistic regression analyses were also performed to 
identify potential haplotypes that are associated with the outcomes of interest. Only   CYBA  
gene polymorphisms that were associated with the primary composite outcome on univari-
ate analyses, using a value of p   !   0.1, were selected for the haplotype analyses. 
    All statistical analyses were performed using SAS software (version 9.1; SAS Institute, 
Cary, N.C., USA). Differences were considered statistically significant at p   !   0.05.
  R e s u l t s  
  Characteristics of the AKI Cohort Stratified by CYBA Gene Polymorphisms  
  Between November 2003 and February 2010, a total of 264 participants were enrolled in 
the study, of which 2 were excluded due to study ineligibility and lack of genomic DNA sam-
pling. The present analysis includes 262 participants who underwent genotyping analyses. 
At enrollment, mean age was 66 years, 53% were men, and 91% were of white ethnicity. Mean 
APACHE II score was 20, and 73% were in the intensive care unit. The majority of the sub-
jects had severe AKI, as defined by the AKI network criteria, with 136 (52%) fulfilling stage-3 
AKI. In-hospital mortality was 22%, 24% required mechanical ventilation, 39% required di-
alysis, and 47% experienced the composite outcome of dialysis requirement or in-hospital 
death. 
    Genotyping was successfully performed on 256–262 subjects. As shown in   table 1  , only 
1 of the 5   CYBA   gene polymorphisms (rs8854) had a minor allele frequency   !  10%. Tests for 
Hardy-Weinberg equilibrium revealed no deviation from expected frequencies with the ex-
ception of the   CYBA   rs1049255 polymorphism. 
    The characteristics of the AKI cohort stratified by the 5   CYBA   gene polymorphisms are 
shown in   table 2  . In brief, overall patient demographics, co-morbidities and disease severity 116
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Table 1. O  bserved and expected distribution of CYBA gene polymorphisms in the AKI cohort
Locus RefSNP
dbSNP
No. 
SNP Domain Samples 
successfully
genotyped, n 
Variant allele 
(frequency)
Hardy-Weinberg 
equilibrium 
  2 p value
CYBA rs8854 –1442  G]A promoter 262  A  (7%)  2.22  0.14 
CYBA rs3794624  383 G]A intron 1 257 A (33%) 0.19 0.66
CYBA rs4673  242 C]T exon 4 
(Tyr72His)
262 T  (38%) 1.71 0.19
CYBA rs4782390 8897  A]T 3-UTR  260 T  (32%) 0.27 0.60
CYBA rs1049255  640 A]G 3-UTR  256 G  (36%) 1.09 <0.0001
Table 2.   Enrollment characteristics of the AKI cohort according to the 5 CYBA gene polymorphisms
Characteristic 
n:
rs8854 
genotypes
p 
value
rs3794624 
genotypes
p 
value
rs4673 
genotypes
p 
value
rs4782390 
genotypes
p 
value
rs1049255 
g enotypes
p 
value
GG 
227
GA/AA 
35
GG 
118
GA/AA 
139
CC 
107
CT/TT 
155
AA
123
AT/TT 
137
AA 
 143
AG/GG 
113
Age, years 66 (15) 66 (18) 0.81  67 (15) 65 (16) 0.38  65 (16) 67 (15) 0.32  66 (15) 65 (16) 0.61  65 (15) 67 (16) 0.53
Males, % 52 60 0.35 52 54 0.72 50 55  0.40 55 50 0.36 54 52  0.80
Race, % 0.83 0.49    0.11 0.003 0.006
White 90 91  90 91 87  93  85 96 95 85
Black 7 6  9 6 8  6  12 2 3 12
Other 3 3  2 3 5  1  3 2 2 3
Contributing cause 
of AKI, % 0.35 0.46 0.34 0.89 0.66
Ischemic 29 20  25 30 26  30  26 30 26 32
Nephrotoxic 15 23  20 13 15  16  17 15 17 15
Septic 9 11  11 8 6  12  10 9 8 10
Multifactorial/other 33 40  32 36 40  29  33 34 37 30
Coexisting conditions, %
DM 45  43  0.86 46 43 0.68 44  45  0.93 40 48 0.18 48  42 0.34
Heart failure  17  9  0.20 16 16 0.95 14  17  0.46 20 13 0.16 15  18 0.62
Cirrhosis 7  11  0.31 9 5 0.26 9  7  0.53 7 8 0.65 8  4 0.12
CLD 19  14  0.51 15 21 0.25 21  17  0.44 21 16 0.29 19  18 0.81
CKD 68  69  0.94 69 68 0.87 70  65  0.52 71 66 0.43 69  65 0.48
APACHE II score  20 (7) 18 (5) 0.176  20 (6) 20 (7) 0.84  19 (6) 20 (7) 0.21  20 (7) 19 (6) 0.23  19 (6) 21 (7) 0.01
Sepsis, %  45 26  0.03 44 42 0.81 37  47  0.09 42 45 0.62 43 43 0.95
Shock, %  30 11  0.02 24 31 0.20 24  30  0.29 22 34 0.04 30 25 0.35
Serum creatinine, mg/dl 
Baseline value  1.6 (0.8) 1.4 (0.5) 0.37  1.6 (0.8) 1.5 (0.6) 0.82  1.6 (0.6) 1.5 (0.8) 0.56  1.6 (0.8) 1.5 (0.6) 0.07  1.5 (0.6) 1.6 (0.8) 0.53
Enrollment value  3.6 (1.8) 3.5 (1.4) 0.96  3.7 (1.9) 3.5 (1.6) 0.46  3.6 (1.7) 3.5 (1.8) 0.55  3.7 (1.8) 3.4 (1.7) 0.20  3.4 (1.6) 3.6 (1.9) 0.36
Peak  4.4 (2.7) 4.1 (1.8) 0.61  4.7 (3.2) 4.1 (1.9) 0.08  4.3 (2.1) 4.4 (2.9) 0.65  4.5 (3.0) 4.2 (2.2) 0.34  4.4 (3.0) 4.3 (2.0) 0.72
Discharge  2.5 (1.7) 2.3 (1.6) 0.37  2.5 (1.8) 2.5 (1.7) 0.89  2.5 (1.6) 2.5 (1.8) 0.85  2.7 (1.9) 2.4 (1.5) 0.12  2.4 (1.7) 2.7 (1.7) 0.18
Urine output, l/day  1.2 (1.1) 1.5 (1.2) 0.25  1.2 (1.0) 1.3 (1.2) 0.69  1.3 (1.2) 1.2 (1.0) 0.33  1.4 (1.1) 1.2 (1.0) 0.12  1.2 (1.0) 1.4 (1.1) 0.39
AKI stage at 
enrollment, %  0.47 0.11 0.41 0.68 0.87
Stage 1  43 43  36 49 43  43  41 46 44  42 
Stage 2  4 9  5 4 7  3  45 5 5  4 
Stage 3  53 49  59 47 50  54  55 49 51  54 
Oxidative stress markers
Plasma nitro-
tyrosine, nM 
12 
(9, 23)
11 
(10, 24)
0.29 12 
(9, 24)
12 
(9, 22)
0.45 12 
(9, 21)
12 
(9, 24)
0.38 12 
(9, 22)
12 
(8, 23)
0.30 12 
(9, 23)
12
(9, 22)
0.21
Urinary 15-F2t-iso-
prostane, ng/mg 
1.1 
(0.6, 2.2)
1.1 
(0.6, 4.0)
0.42 1.1 
(0.6, 2.8)
1.1 
(0.6, 2.0)
0.49 1.2
(0.6, 2.6)
1.0
(0.6, 2.0)
0.56 1.0
(0.5, 2.0)
1.2 
(0.6, 2.4)
0.87 1.2
(0.7, 2.7)
0.9
(0.5, 1.7)
0.73
CKD  = Chronic kidney disease; CLD = chronic lung disease; DM = diabetes mellitus. Continuous variables are presented as means (SD) or medians (25th, 75th percentile), 
and categorical variables as percentages. Missing genotyping data: rs3794624 (n = 5), rs4782390 (n = 2), and rs1049255 (n = 6).117
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measures did not significantly differ across genotypes, with a few notable exceptions. The 
  CYBA   rs8854 minor A-allele (GA/AA genotype) group had a lower prevalence of sepsis (p = 
0.03) and shock (p = 0.02) compared with the GG genotype group; the   CYBA   rs4782390 mi-
nor T-allele (AT/TT genotype) group had a higher prevalence of shock (p = 0.04) compared 
with the AA genotype group, and the   CYBA   rs1049255 minor G-allele (AG/GG genotype) 
group had a higher APACHE II score (p = 0.01) compared with the AA genotype group. A 
genotype-phenotype association was not demonstrable between individual  CYBA  gene poly-
morphisms and 2 markers of oxidative stress, plasma nitrotyrosine and urinary 15-F  2t -iso-
prostane levels (  table 2  ).
    CYBA Gene Polymorphisms and Adverse Outcomes 
  Compared with the GG genotype group, the   CYBA   rs8854 A-allele group experienced 
less dialysis requirement or in-hospital death (50 vs. 29%; p = 0.02).  Figure 1  displays the out-
come of dialysis requirement or in-hospital death stratified by   CYBA   rs8854 genotypes and 
APACHE II score tertiles. The outcome of dialysis requirement or in-hospital death was 
overall less frequent among A-allele carriers within each APACHE II score tertile but within 
the highest APACHE II score tertile, the composite outcome was significantly lower in the 
  CYBA   rs8854 A-allele compared with the GG genotype group (40 vs. 80%; p = 0.006). 
  As shown in  table 3 , the  CYBA  rs8854 A-allele group had an unadjusted OR of 0.40 (95% 
CI 0.19–0.88) for the outcome of dialysis requirement or in-hospital death compared with 
the GG genotype group. This association persisted after adjustment for sex, race, and age (OR 
0.39; 95% CI 0.18–0.85), as well as sex, race, and APACHE II score (OR 0.41; 95% CI 0.18–
0.96). A similar association was observed after adjustment for sex, race, APACHE II score, 
and sepsis (data not shown). The   CYBA   rs8854 A-allele group was also associated with the 
secondary outcome of dialysis requirement, assisted mechanical ventilation, or in-hospital 
death after adjustment for sex, race, and age (OR 0.42; 95% CI 0.20–0.89), as well as sex, race 
and APACHE II score (OR 0.43; 95% CI 0.18–0.99).
    By contrast, the   CYBA   rs4673 T-allele and rs1049255 G-allele group had an unadjusted 
OR of 1.69 (95% CI 1.03–2.79) and 1.66 (95% CI 1.01–2.73) for the outcome of dialysis require-
ment or in-hospital death compared with the CC genotype and AA genotype group, respec-
tively ( table 3 ). These associations were attenuated after adjustment for sex, race, and age, but 
became non-significant once adjusted for the APACHE II score. There was not any associa-
tion between the  CYBA  rs3794624 or rs4782390 polymorphism and the primary and second-
ary composite outcomes (  table 3  ).
  Fig. 1.   Dialysis requirement or 
in-hospital death in the AKI 
cohort stratified by the   CYBA  
rs8854 genotypes and APACHE 
II score tertiles.   *   p = 0.006 vs. 
GG genotype in the APACHE II 
score upper tertile. 118
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    CYBA Haplotypes and Adverse Outcomes 
  We next generated a Haploview plot on 4   CYBA   gene polymorphisms after exclusion of 
rs1049255, which did not fulfill Hardy-Weinberg equilibrium.   Figure 2   displays the LD plot 
at the   CYBA   gene locus with representation of the 4 variants analyzed in our study cohort. 
The LD plot revealed substantial correlation (as defined by the D     parameter) across the 
    8-kbp human   CYBA   locus, with the rs8854 and rs4673 polymorphisms displaying the 
highest correlation, as evidenced by a D     parameter of 85 (on a scale of 0–100). 
  Finally, we conducted haplotype analyses after excluding the polymorphism that did not 
fulfill the Hardy-Weinberg equilibrium (rs1049255). The most frequent haplotype was A-A-
G-G estimated on 186 chromosomes with a frequency of 56.5%. As shown in   table 3  , the 
Table 3. A  ssociation of the 5 CYBA gene polymorphisms with adverse outcomes in the AKI cohort
Predicted variable Dialysis requirement or in-hospital 
death
Dialysis requirement, mechanical 
ventilation, or in-hospital death
O  R 95% CI p value  OR 95% CI p value
rs8854 (A-allele vs. G/G)
Unadjusted  0.40 0.19, 0.88 0.02 0.43 0.20, 0.90 0.03
Model 1  0.39 0.18, 0.85 0.02 0.42 0.20, 0.89 0.02
Model 2  0.41 0.18, 0.96 0.04 0.43 0.18, 0.99 0.05
rs3794624 (A-allele vs. G/G)
Unadjusted  0.92 0.56, 1.50 0.73 1.07 0.65, 1.75 0.79
Model 1  0.91 0.55, 1.49 0.71 1.06 0.65, 1.73 0.82
Model 2  0.93 0.54, 1.62 0.80 1.17 0.66, 2.07 0.59
rs4673 (T-allele vs. C/C)
Unadjusted  1.69 1.03, 2.79 0.04 1.37 0.83, 2.24 0.21
Model 1  1.66 1.00, 2.74 0.05 1.35 0.82, 2.23 0.24
Model 2  1.53 0.88, 2.68 0.13 1.19 0.67, 2.11 0.55
rs4782390 (T-allele vs. A/A)
Unadjusted  0.84 0.52, 1.37 0.45 1.12 0.69, 1.82 0.65
Model 1  0.82 0.49, 1.35 0.43 1.07 0.65, 1.77 0.78
Model 2  0.92 0.53, 1.60 0.77 1.37 0.77, 2.45 0.29
rs1049255 (G-allele vs. A/A)
Unadjusted  1.66 1.01, 2.73 0.05 1.44 0.88, 2.37 0.15
Model 1  1.74 1.04, 2.89 0.03 1.51 0.91, 2.51 0.11
Model 2  1.36 0.77, 2.41 0.29 1.08 0.60, 1.96 0.79
A-A-G-G haplotypea
Unadjusted 0.07 0.09
1 copy (vs. none) 1.81 1.07, 3.08 0.03 1.58 0.93, 2.69 0.09
2 copies (vs. none) 1.06 0.50, 2.23 0.88 0.77 0.37, 1.61 0.48
Model 1  0.09 0.12
1 copy (vs. none) 1.76 1.03, 3.01 0.04 1.55 0.91, 2.66 0.11
2 copies (vs. none) 1.06 0.50, 2.24 0.88 0.78 0.37, 1.64 0.50
Model 2  0.09 0.05
1 copy (vs. none) 1.80 0.99, 3.29 0.05 1.61 0.86, 3.01 0.13
2 copies (vs. none) 0.87 0.38, 2.00 0.75 0.54 0.23, 1.28 0.16
Mo  del 1 is adjusted for sex, race, and age; model 2 is adjusted for sex, race, and APACHE II score.
a The haplotype was generated from the CYBA rs4782390, rs4673, rs3794624, and rs8854 polymor-
phisms that were in Hardy-Weinberg equilibrium.119
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presence of one copy of this common haplotype was associated with an OR of 1.81 (95% CI 
1.07–3.08) for the outcome of dialysis requirement or in-hospital death, which persisted after 
adjustment for sex, race, and age (OR 1.76; 95% CI 1.03–3.01), but was attenuated after adjust-
ment for sex, race, and APACHE II score (OR 1.80; 95% CI 0.99–3.29). The haplotype A-A-
G-G association was directionally consistent with that observed for the   CYBA   rs4673 poly-
morphism. Of note, however, there was no association with the presence of two copies of the 
  CYBA   A-A-G-G haplotype. 
  Discussion   
  In the present study, we examined the relationship of 5 polymorphisms in the   CYBA  
gene locus located in the promoter (rs8854), intron-1 (rs3794624), exon-4 (rs4673), and 
3    -UTR (rs4782390 and rs1049255) regions, with adverse clinical outcomes in a large cohort 
of hospitalized patients with AKI. The observed and expected genotype frequencies were not 
significantly different, with the exception of   CYBA   rs1049255, which did not fulfill Hardy-
Weinberg equilibrium. Although the overall population was 91% white, there were no race, 
sex, or age differences within genotype groups with the exception of   CYBA   rs4782390 and 
rs1049255, which displayed race differences in allele frequencies. There was no demonstrable 
genotype-phenotype association between the 5   CYBA   gene polymorphisms and the two se-
lected markers of oxidative stress, plasma nitrotyrosine and urinary 15-F  2t -isoprostane  lev-
els. The   CYBA   rs8854 A-allele group experienced a lower requirement for the   primary   com-
posite outcome of dialysis requirement or in-hospital death even among patients with the 
highest APACHE II score. After adjustment for sex, race, and APACHE II score, the   CYBA  
rs8854 A-allele group also experienced lower odds for this adverse outcome as well as for the 
  secondary   composite of dialysis requirement, assisted mechanical ventilation or in-hospital 
death. By contrast, the   CYBA   rs4673 T-allele and rs1049255 G-allele groups had higher un-
adjusted odds for dialysis requirement or in-hospital death, which became non-significant 
once adjusted for the APACHE II score. We found no association between the   CYBA 
 rs3794624 or rs4782390 polymorphisms and the two outcomes of interest. Finally, we identi-
  Fig. 2.    CYBA   gene locus Haploview plot in the AKI 
cohort. The Haploview plot was generated on 4 
  CYBA   gene polymorphisms after exclusion of 
rs1049255, which did not fulfill the Hardy-Wein-
berg equilibrium. The plot illustrates pairwise LD 
between all polymorphisms based on D     values. 
The darker a rhombus appears, the higher the LD 
is between the respective polymorphisms. 120
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fied a common haplotype (generated from the   CYBA   rs4782390, rs4673, rs3794624, and 
rs8854 polymorphisms) whereby the presence of a single copy, not 2 copies, was associated 
with higher odds for the primary outcome. 
  NADPH oxidase is a key enzyme that catalyzes the production of superoxide, mediating 
the downstream generation and injurious effects of ROS. This enzyme is highly expressed in 
neutrophils and endothelial cells   [30]   and possesses several subunits, including the p22  phox  
subunit, which serves as the final transporter transferring an electron from NADPH to mo-
lecular oxygen. This key electron transfer protein is encoded by the   CYBA   gene. Given its 
importance in mediating oxidative stress-mediated cellular injury in response to ischemic 
and toxic kidney injury, one might anticipate that polymorphisms disrupting the function 
or expression of the NOX p22  phox   subunit would alter oxidative stress–mediated cellular re-
sponses in AKI. Several polymorphisms have been described in the  CYBA  gene that are vari-
ably linked to measures of oxidative stress, including the   CYBA   rs1049255 (3   -UTR)  poly-
morphism, which has been associated with lower mRNA and protein expression and reduced 
NOX activity   [22, 23, 31, 32]  , the   CYBA   rs4673 (Tyr  72 His, exon 4) polymorphism (associated 
with reduced NOX activity   [21]  ); the   CYBA   rs9932581 (not studied here) polymorphism 
(linked to higher promoter activity   [32]   and increased NOX activity   [20]  ), and the   CYBA 
  rs8854 (upstream, promoter) polymorphism (not linked to a change in NOX activity   [33]  ). 
In recent years, the relationship between genetic variability in the   CYBA   gene and disease 
has become a topic of interest. Indeed, genetic studies of cardiovascular disease examining 
the influence of these polymorphisms have yielded conflicting results. Specifically, the  CYBA  
rs1049255 (3  -UTR) polymorphism was linked to increased disease susceptibility; the  CYBA 
 rs4673  (Tyr 72  His) and rs9932581 polymorphisms to decreased disease susceptibility   [34, 35]  , 
and the rs4673 polymorphism to disease progression   [36]  . Genetic studies of kidney disease 
have shown a protective effect of the   CYBA   rs4673 polymorphism against the development 
of chronic kidney failure   [37]  , and in a previously reported subgroup of the present study 
cohort, we found the rs4673 polymorphism to be associated with higher odds for dialysis 
requirement or in-hospital death   [13]  . In the present study, the effect estimate of this poly-
morphism was in the same direction but was attenuated in the adjusted analyses. 
    In the present study, the potential mechanisms underlying the harmful association of 
the common   CYBA   A-A-G-G haplotype with the composite of dialysis requirement or in-
hospital death are unknown. We propose that the worse outcomes observed amongst carriers 
of this haplotype might in part be due to the increased generation of ROS by NOX residing 
in neutrophils and endothelial cells, resulting in more extensive organ injury. However, this 
hypothesis requires further study. 
    To our knowledge, this is the first comprehensive study testing the comprehensive hy-
pothesis of whether 5 representative polymorphisms spanning the entire   CYBA   gene locus 
associate with clinical outcomes in patients with AKI. The heterogeneity of our cohort was 
offset by the selective inclusion of subjects with more advanced AKI requiring formal ne-
phrology consultation. Although sizeable, our cohort was relatively small for genetic epide-
miological studies, but 91% of the study cohort were white, reducing the potential impact of 
race and ethnicity on genotype prevalence. Although we found some ethnic differences in 
allele frequencies among the   CYBA   rs4782390 and rs1049255 genotypes, when the analyses 
were adjusted for race/ethnicity, the point estimates were not significantly altered. The use 
of the APACHE II score as a covariate to reflect the severity of illness strengthens the plau-
sibility of our results. Finally, our composite endpoints were chosen to account for survival 
bias when dialysis requirement and assisted mechanical ventilation are being assessed as 
outcome measures. 
    The present study suffers from several limitations. First, the   CYBA   rs1049255 polymor-
phism did not fulfill the Hardy-Weinberg equilibrium. A similar deviation has previously 121
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